Project Grant K01OH012671

The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a 5-year, $678,927 Project Grant to The Medical College of Wisconsin to conduct a randomized study on improving adherence to oral endocrine therapy in breast cancer patients. The intervention involves routine symptom monitoring using patient-reported outcomes and clinical pharmacy team follow-up to help patients manage symptoms and barriers to taking their daily medications. The study aims to assess the impact on...

This $656,560 federal Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program aims to comprehensively characterize oral anticancer medication (OAM) adherence and identify factors influencing adherence and associated health outcomes among patients with hematologic malignancies. The 5-year study, starting August 1, 2024, will use a prospective, mixed-methods design to analyze OAM adherence initiation and persistence over 1...

This $251,519 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support the development, refinement, and pilot testing of a nurse-led coping and supportive care intervention called "TRANSITIONS" to address the psychosocial needs of patients with triple-negative breast cancer (TNBC) as they transition from curative therapy to surveillance. The Principal Investigator, Dr. Kathryn Post, will lead this 5-year project at...

This $465,020 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Maryland, Baltimore to investigate how chemotherapy used to treat ovarian cancer can inadvertently stimulate tumor-associated enzymes that promote metastasis. The goal is to determine the specific mechanisms by which chemotherapy activates these enzymes, in order to develop strategies to neutralize the pro-metastatic effects. The 5-year research...

The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $662,761 Cooperative Agreement to the Dartmouth-Hitchcock Clinic to develop and test a video intervention that helps parents of children with cancer discuss goals of care and make treatment decisions that align with their values. The award period runs from September 2024 to August 2026. The project aims to build the infrastructure and conduct a large randomized trial of the...

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $257,413 to the Dartmouth-Hitchcock Clinic to develop and evaluate an interactive visual aid (VIS) that can facilitate patient-clinician communication and shared understanding around decisions to stop cancer treatment for patients with advanced cancer. The key objectives are to: 1) Assess patient-caregiver-clinician shared understanding following serious illness conversations in...

The National Cancer Institute (NCI) awarded a $356,850 Cooperative Agreement (CFDA 93.395 - Cancer Treatment Research) to Oregon Health & Science University (OHSU) to characterize the pre-analytical steps involved in blood and bone marrow biopsy sample handling and storage/retrieval for functional assay reporting. The project aims to establish pre-analytical sample processing guidelines to enable maximal reproducibility for functional testing outcomes, including high throughput-drug...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $293,053 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to refine and pilot test a supportive psychosocial intervention for patients with malignant primary central nervous system (CNS) tumors. The intervention, which incorporates elements of Acceptance and Commitment Therapy, aims to alleviate distress and promote adaptive...

This $293,053 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports a 5-year project to refine and pilot test a specialized palliative care intervention (PEACE) for patients with hematologic malignancies receiving adoptive cellular therapy (ACT) and their caregivers. The project aims to 1) refine the PEACE intervention based on findings from an open pilot study, 2) determine the feasibility and acceptability of PEACE through a pilot...

This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...